Solvay Pharmaceuticals, Gmbh

Abbott Products Gmbh

Abbott Healthcare Products B.v.

Michael Weske

Dieter Ziegler

Yvan Fischer

Josef Messinger

Yasmin Karimi-Nejad

Lechoslaw Turski

Reinhard Brueckner

Dagmar Hoeltje

Axel Pahl

Michael Mlinaric

Hrissanthi Ikonomidou

Klaus Witte

Katrin Michaelis

Brian Moloney

Constanze Hoefer

Lester Marrison

Christiane Boecker

Samuel David

Jochen Antel

Ulf Preuschoff

Holger Sann

Johannes Hebebrand

Pasi Koskimies

Heinrich-Hubert Thole

Bettina Husen

Lila Pirkkala

Willy Deleersnijder

David Sykes

Lila Kallio

Substituted steroid compounds which represent selective inhibitors of 17&#x3b2;-hydroxysteroid dehydrogenase type I (17&#x3b2;-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17&#x3b2;-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17&#x3b2;-estradiol concentration.

17-beta HSD1 and STS inhibitors

Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.

Screening and treatment methods using IGS5 enzymes of the metalloprotease family

Compounds corresponding to formula I, wherein R, R, R, R, R, R, R, R, R, Rand n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

[object Object]

The present invention relates to novel substituted steroid derivatives which represent selective inhibitors of the 17&#x3b2;-hydroxysteroid dehydrogenase type I (17&#x3b2;-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17&#x3b2;-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17&#x3b2;-estradiol concentration.

17&#x3b2;-HSD1 and STS inhibitors

The use of compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description for treating cardiac arrhythmias and other disease states.

Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R, R, Rand Rhave the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them

Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them

Compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds.

Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

Method of preparing pharmaceutical compositions

Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R, R, Rand Rhave the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Method of treating or inhibiting obesity

Method of identifying compounds suitable for treatment and/or prophylaxis of obesity

Growing community of inventors

Burgdorf, Germany

Michael Weske